StockDocs
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
NBIX

Neurocrine Biosciences, Inc.

NBIX Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗
$166.23
-19.27 -10.39%

Key statistics

from XBRL data in SEC filings
Market cap
$16.9B
Revenue (TTM)
$3.37B
Net income (TTM)
$706M
EPS (TTM)
$6.83
P/E ratio
24.3
Dividend yield
Free cash flow
$749M
Cash
$332M
Total assets
$5.36B
Gross margin
52-week range
$122.14 – $186.12

Recent SEC filings

40 most recent
Annual, quarterly & current reports
8-K/A Jul 31, 2026 10-Q Quarter ended 2026-06-30 Jul 31, 2026 8-K Results of operations (earnings release) Jul 30, 2026 8-K Director or officer change; Shareholder vote results May 28, 2026 8-K Entered a material agreement; Completed an acquisition or disposition; Took on a direct financial obligation; Regulation FD disclosure May 18, 2026 10-Q Quarter ended 2026-03-31 May 5, 2026 8-K Results of operations (earnings release) May 5, 2026 8-K Entered a material agreement Apr 6, 2026 10-K Fiscal year ended 2025-12-31 Feb 11, 2026 8-K Results of operations (earnings release) Feb 11, 2026 8-K Director or officer change Nov 24, 2025 10-Q Quarter ended 2025-09-30 Oct 28, 2025 8-K Results of operations (earnings release) Oct 28, 2025 10-Q Quarter ended 2025-06-30 Jul 30, 2025 8-K Results of operations (earnings release) Jul 30, 2025 8-K Director or officer change May 30, 2025 8-K Director or officer change; Shareholder vote results May 22, 2025 10-Q Quarter ended 2025-03-31 May 5, 2025 8-K Results of operations (earnings release) May 5, 2025 8-K Director or officer change; Regulation FD disclosure Apr 4, 2025 10-K Fiscal year ended 2024-12-31 Feb 10, 2025 8-K Results of operations (earnings release) Feb 6, 2025 8-K Entered a material agreement; Regulation FD disclosure Jan 27, 2025 8-K Other events Dec 20, 2024 8-K Other events Nov 1, 2024 10-Q Quarter ended 2024-09-30 Oct 30, 2024 8-K Results of operations (earnings release) Oct 30, 2024 8-K Director or officer change Oct 11, 2024 8-K Regulation FD disclosure; Other events Aug 28, 2024 10-Q Quarter ended 2024-06-30 Aug 1, 2024 8-K Results of operations (earnings release) Aug 1, 2024 8-K Director or officer change; Amended charter or bylaws May 28, 2024 8-K Director or officer change; Shareholder vote results May 23, 2024 10-Q Quarter ended 2024-03-31 May 1, 2024 8-K Results of operations (earnings release) May 1, 2024 10-K Fiscal year ended 2023-12-31 Feb 9, 2024 8-K Results of operations (earnings release) Feb 7, 2024 8-K Other events Nov 13, 2023 8-K Other events Nov 9, 2023 10-Q Quarter ended 2023-09-30 Oct 31, 2023